The changing face of fungal infections in health care settings.
As strategies to prevent invasive fungal infections among both hospitalized and nonhospitalized patients have evolved, the epidemiology of these infections has changed. Several unique features of select Candida species and molds have facilitated the emergence of these pathogens as more-common causes of infection than in previous years. In this context, the changing pathogen profiles, unique antifungal susceptibilities, and approaches to treatment are outlined.
Fridkin
Scott K
SK
Mycotic Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. skf0@cdc.gov
D000935:Antifungal Agents / Q000627:therapeutic use; D021821:Communicable Diseases, Emerging / Q000453:epidemiology / Q000382:microbiology; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology*; D016469:Fungemia / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D006801:Humans; D015994:Incidence; D009181:Mycoses / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D012307:Risk Factors
D000935:Antifungal Agents